CIK 0001326190 · Non-accelerated filer<br>Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 202726770
- Phone
- 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-05-21 | Enright William President and CEO | Grant or award · Stock Options (option to buy) | +103,158 | 103,158 | ||
| 2018-05-16 | Novartis Bioventures Ltd 10% owner | Other acquisition | +767,728 | 4,876,479 | ||
| 2018-05-16 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 689.87 | ||
| 2018-05-15 | Novartis Bioventures Ltd 10% owner | Other acquisition | +274,703 | 4,108,751 | ||
| 2018-04-16 | Novartis Bioventures Ltd 10% owner | Other acquisition | +482,907 | 3,616,889 | ||
| 2018-04-16 | Novartis Bioventures Ltd 10% owner | Other acquisition | +217,159 | 3,834,048 | ||
| 2018-04-16 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 1,034.81 | ||
| 2018-04-05 | SAYARE MITCHEL Director | Grant or award · Stock Options (option to buy) | +35,000 | 35,000 | ||
| 2018-03-15 | Novartis Bioventures Ltd 10% owner | Other acquisition | +261,969 | 3,133,982 | ||
| 2018-03-15 | Novartis Bioventures Ltd 10% owner | Other disposition · Series B Convertible Preferred Stock | −344.94 | 1,379.75 | ||
| 2018-02-15 | Truffle Capital S.A.S. 10% owner | Other acquisition | +4,483 | 179,427 | ||
| 2018-02-15 | Truffle Capital S.A.S. 10% owner | Other acquisition | +5,977 | 139,184 | ||
| 2018-02-15 | Truffle Capital S.A.S. 10% owner | Other acquisition | +4,483 | 76,700 | ||
| 2018-02-15 | Novartis Bioventures Ltd 10% owner | Other acquisition | +67,925 | 2,872,013 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other acquisition | +17,789 | 174,944 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other acquisition | +23,719 | 133,207 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other acquisition | +17,789 | 72,217 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −22.77 | 113.83 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −30.35 | 151.77 | ||
| 2018-02-13 | Truffle Capital S.A.S. 10% owner | Other disposition · Series B Convertible Preferred Stock | −22.77 | 113.83 |
Page 26 of 29 · 568 trades